Search
A research team from Uppsala University in Sweden has triumphantly implanted genetically edited donor islet beta cells into a patient with type 1 diabetes, leveraging CRISPR-Cas gene editing technology. Remarkably, these cells persisted and functioned effectively for 12 weeks without the necessity of immunosuppressants. The cornerstone of this technological breakthrough lies in the precise deletion of specific genes and the expression of the CD47 protein, which significantly reduces immune rejection. Continuous monitoring revealed that the transplanted cells did not elicit an immune response, and the patient's glycated hemoglobin levels underwent a notable decline. This monumental achievement offers fresh hope for the eventual cure of type 1 diabetes.
-
C114 Communication Network -
Communication Home
